-
1
-
-
73149115341
-
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
-
Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 5538-5546
-
-
Johnston, S.1
Pippen, J.2
Pivot, X.3
-
2
-
-
33749074278
-
Erbb receptors and their ligands in the breast
-
Zahnow CA: ErbB receptors and their ligands in the breast. Expert Rev Mol Med 8:1-21, 2006
-
(2006)
Expert Rev Mol Med
, vol.8
, pp. 1-21
-
-
Zahnow, C.A.1
-
3
-
-
34547676475
-
Erbb receptors: From oncogenes to targeted cancer therapies
-
Zhang H, Berezov A, Wang Q, et al: ErbB receptors: From oncogenes to targeted cancer therapies. J Clin Invest 117:2051-2058, 2007
-
(2007)
J Clin Invest
, vol.117
, pp. 2051-2058
-
-
Zhang, H.1
Berezov, A.2
Wang, Q.3
-
4
-
-
33748192481
-
The erbb2 signaling network as a target for breast cancer therapy
-
Badache A, Goncalves A: The ErbB2 signaling network as a target for breast cancer therapy. J Mammary Gland Biol Neoplasia 11:13-25, 2006
-
(2006)
J Mammary Gland Biol Neoplasia
, vol.11
, pp. 13-25
-
-
Badache, A.1
Goncalves, A.2
-
5
-
-
0024337144
-
Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
-
(1989)
Science
, vol.244
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
-
6
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the her-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
7
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of her2-overexpressing metastatic breast cancer
-
Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
-
(2002)
J Clin Oncol
, vol.20
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
-
8
-
-
46449113024
-
Efficacy and safety of lapatinib as first-line therapy for erbb2-amplified locally advanced or metastatic breast cancer
-
Gomez HL, Doval DC, Chavez MA, et al: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26:2999-3005, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 2999-3005
-
-
Gomez, H.L.1
Doval, D.C.2
Chavez, M.A.3
-
9
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses Her2
-
Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
10
-
-
0036534121
-
Phase ii study of weekly docetaxel and trastuzumab for patients with her-2-overexpressing metastatic breast cancer
-
Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808, 2002
-
(2002)
J Clin Oncol
, vol.20
, pp. 1800-1808
-
-
Esteva, F.J.1
Valero, V.2
Booser, D.3
-
11
-
-
78349268795
-
A single-arm phase ii trial of first-line paclitaxel in combination with lapatinib in her2-overexpressing metastatic breast cancer
-
Jagiello-Gruszfeld A, Tjulandin S, Dobrovolskaya N, et al: A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. Oncology 79:129-135, 2010
-
(2010)
Oncology
, vol.79
, pp. 129-135
-
-
Jagiello-Gruszfeld, A.1
Tjulandin, S.2
Dobrovolskaya, N.3
-
12
-
-
57149096463
-
Phase iii, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
-
Di Leo A, Gomez HL, Aziz Z, et al: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544-5552, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 5544-5552
-
-
Di Leo, A.1
Gomez, H.L.2
Aziz, Z.3
-
13
-
-
33847147996
-
The combination of letrozole and trastuzumab as first or second-line biologic therapy produces durable responses in a subset of her2 positive and er positive advanced breast cancers
-
Marcom PK, Isaacs C, Harris L, et al: The combination of letrozole and trastuzumab as first or second-line biologic therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102:43-49, 2007
-
(2007)
Breast Cancer Res Treat
, vol.102
, pp. 43-49
-
-
Marcom, P.K.1
Isaacs, C.2
Harris, L.3
-
14
-
-
77949884661
-
Randomized study of lapatinib alone or in combination with trastuzumab in women with erbb2-positive, trastuzumab-refractory metastatic breast cancer
-
Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 1124-1130
-
-
Blackwell, K.L.1
Burstein, H.J.2
Storniolo, A.M.3
-
15
-
-
22344446208
-
Randomized phase ii trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The m77001 study group
-
Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005
-
(2005)
J Clin Oncol
, vol.23
, pp. 4265-4274
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
-
16
-
-
84862914692
-
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
-
Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
-
(2012)
N Engl J Med
, vol.366
, pp. 109-119
-
-
Baselga, J.1
Cortés, J.2
Kim, S.B.3
-
17
-
-
84866536687
-
Open-label phase iii randomized controlled trial comparing taxane-based chemotherapy (tax) with lapatinib (l) or trastuzumab (t) as first-line therapy for women with her2 metastatic breast cancer: Interim analysis (ia) of ncic ctg ma.31/gsk egf 108919
-
Gelmon KA, Boyle F, Kaufman B, et al: Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2 metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 30, 2012 (suppl; abstr LBA671)
-
(2012)
J Clin Oncol
, vol.30
-
-
Gelmon, K.A.1
Boyle, F.2
Kaufman, B.3
-
20
-
-
84857236823
-
Lapatinib with trastuzumab for her2-positive early breast cancer (neoaltto): A randomised, open-label, multicentre, phase 3 trial
-
Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 379:633-640, 2012
-
(2012)
Lancet
, vol.379
, pp. 633-640
-
-
Baselga, J.1
Bradbury, I.2
Eidtmann, H.3
-
21
-
-
85022342264
-
Correlation of clinical and molecular findings with pathologic response to preoperative lapatinib and trastuzumab, separately or in combination, prior to neoadjuvant chemotherapy for her2-positive breast cancer
-
Holmes FA, Espina VA, Liotta LA, et al: Correlation of clinical and molecular findings with pathologic response to preoperative lapatinib and trastuzumab, separately or in combination, prior to neoadjuvant chemotherapy for HER2-positive breast cancer. Presented at San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011
-
San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011
-
-
Holmes, F.A.1
Espina, V.A.2
Liotta, L.A.3
-
22
-
-
84864018421
-
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase ii cher-lob study
-
Guarneri V, Frassoldati A, Bottini A, et al: Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study. J Clin Oncol 30:1989-1995, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 1989-1995
-
-
Guarneri, V.1
Frassoldati, A.2
Bottini, A.3
-
23
-
-
84856444501
-
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (gepar-quinto, gbg 44): A randomised phase 3 trial
-
Untch M, Loibl S, Bischoff J, et al: Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (Gepar-Quinto, GBG 44): A randomised phase 3 trial. Lancet Oncol 13:135-144, 2012
-
(2012)
Lancet Oncol
, vol.13
, pp. 135-144
-
-
Untch, M.1
Loibl, S.2
Bischoff, J.3
|